SHBG and Insulin resistance: It has been reported that COC containing of 30 μg ethynilestradiol and 3 mg drospirenone for six months significantly increased plasma SHBG from 37.31 nmol/L to 179.01 nmol/L, with an average increase of 141.7 nmol/L (p = 0.002) but COC use has also been associated with impaired fasting glucose, insulin resistance and increased risk of thromboembolism disease [107,108].